Introduction

Adenine phosphoribosyltransferase (APRT) deficiency is an uncommon, autosomal recessive disorder of purine metabolism [1]. The most common clinical manifestation of APRT deficiency is formation of a kidney stone. APRT deficiency can also produce crystal nephropathy that may lead to chronic kidney disease (CKD). However, a significant number of patients remain asymptomatic. There is no specific manifestation of this disease; therefore, awareness of APRT deficiency is important to diagnose this condition. We present a patient with rapidly progressive renal failure secondary to dihydroxyadenine (DHA) crystal-induced nephropathy that was confirmed by kidney biopsy. Timely diagnosis and treatment resulted in rapid improvement of the patient’s renal function.

Case report

A 24-year-old female born to a consanguineously married couple presented with complaints of nausea, vomiting, anorexia, and fatigue for three months. There was no history of pedal edema, decreased urine output, or intake of any nephrotoxic drugs. The patient denied a family history of similar illness.

Her clinical examination was unremarkable. Her laboratory investigations revealed serum creatinine of 1.86 mg/dL, which further increased to 2.4 mg/dL within four days of admission. Serum complement levels were within normal range. Her serum calcium was 11.2 mg/dL, 25-hydroxyvitamin D was 175 nmol/L (50–250 nmol/L), and parathormone was 1.28 pmol/L (1.3–6.8 pmol/L). Serum sodium was 137 mmol/L, and serum potassium was 4.16 mmol/L.

Her blood count revealed hemoglobin 10.7 g/dL, total leucocyte count 8,900 × 10⁹/L, and platelet count 279 × 10⁹/L. Renal ultrasound revealed normal sized kidneys with no renal stones. Urinalysis showed 7.2 pH, no red blood cells, and 10 to 15 white blood cells/high power field. Urine culture showed no growth.

With a provisional diagnosis of tubulointerstitial dis-
ease, a renal biopsy was performed and revealed two cores of renal parenchyma with 25 unremarkable glomeruli with predominantly tubulointerstitial injury. The tubular lumen revealed numerous brown-green crystals of varying shapes (rod, rhomboid, granular, fan shaped or radially arranged), eliciting foreign body reactions (Fig. 1A). These crystals were also seen in the cytoplasm of tubular epithelial cells, interstitium, blood vessels, and macrophages (Fig. 1B, C). These crystals were weak periodic acid–Schiff positive, argyrophilic with silver methenamine, and bluish green on Masson’s trichrome stain (Fig. 1D, E). The crystals were birefringent under polarizing microscopy (Fig. 1F). The crystals showed a characteristic brownish color, and DHA crystal-induced nephropathy was diagnosed.

A repeat urine sample was analyzed, and light microscopy of the urine sediment showed 2,8-DHA crystals. Polarization of these crystals revealed the characteristic Maltese cross pattern (Fig. 2). The patient was started on allopurinol and prescribed a low salt, low fat, and

![Figure 1. Renal biopsy findings.](image1)

(A) Marked tubular atrophy, interstitial inflammation, and fibrosis are shown. Higher magnification shows 2,8-dihydroxyadenine (DHA) crystals within the tubular lumens (B) with giant cell reaction in the interstitium and also in the vascular lumen (C). (D, E) The crystals are argyrophilic with silver methenamine and bluish green on Masson’s trichrome stain. (F) The crystals are seen within a tubular lumen under polarized light microscopy.

![Figure 2. Urine examination (x40).](image2)

(A) The typical brown dihydroxyadenine crystals have a dark outline and central spicules in conventional light microscopy. (B) The crystals appear yellow under polarized light microscopy.
high fluid diet. Her constitutional symptoms rapidly improved. The patient was asymptomatic with normal renal function at the six month follow-up visit.

**Discussion**

The APRT enzyme is necessary for the metabolism of adenine to adenosine monophosphate in the presence of phosphoribosyl pyrophosphate. With deficiency of the APRT enzyme, xanthine dehydrogenase (XDH) converts adenine to 2,8 DHA, which is excreted by the kidneys. DHA is protein bound in plasma, but it is insoluble in urine at any physiological pH, which leads to crystalluria and, less commonly, crystalline nephropathy (Fig. 3).

Nearly 10% of patients with DHA crystaluria progress toward end stage renal disease and may require renal replacement therapy [2]. In many cases, the diagnosis of APRT deficiency was first recognized after dysfunction of a transplanted kidney [3,4]. At least 50% of patients with DHA crystaluria are asymptomatic until adulthood, and their CKD is usually attributed to obstructive uropathy and nephrolithiasis-related chronic tubulointerstitial nephritis. The exact cause of the phenotypic variability is not known; however, hydration status and excess intake of purine-rich food can affect presentation [5,6]. In our case, hypercalcemia could have acted as a triggering factor for crystallization. Although the etiology of hypercalcemia in our patient could not be ascertained, the treating team thought it could be due to consumption of calcium and vitamin D for her spondylolisthesis. Because the patient improved after initiation of treatment, a second kidney biopsy was not ethical, and the hypothesis of hypercalcemia triggering crystallization could not be confirmed.

Diagnosis of APRT deficiency is suggested by 1) detection of urinary 2,8-DHA crystals, 2) histologic findings of crystal nephropathy, and 3) kidney stone analysis. The disease can be confirmed by 1) genetic testing and 2) demonstration of absence to APRT activity in red blood cell lysate.

APRT deficiency is a rare disease. However, misidentification of 2,8-DHA crystals (radiolucent kidney stones) as uric acid calculi or xanthine stones is a significant cause of delayed diagnosis. We summarize the differences in the appearance of DHA crystals, uric acid stones, oxalate, and xanthine stones in Table 1.

**Figure 3. Mechanisms of adenine phosphoribosyltransferase (APRT) deficiency.** Adenine cannot be converted to adenosine and is thus oxidized to 2,8 dihydroxyadenine (DHA) by xanthine dehydrogenase (XDH) via an 8-hydroxy intermediate. AMP, adenosine monophosphate.

**Table 1. Salient features of the differential diagnosis in patients with metabolic crystalline nephropathy**

| Variable                  | 2,8 DHA            | Oxalate                      | Urate                        |
|---------------------------|--------------------|------------------------------|------------------------------|
| **Color**                 | Brownish-green: H&E and PAS | Transparent                  | Transparent                  |
|                           | Light blue: Trichrome |                              |                              |
|                           | Black: Silver stain |                              |                              |
| **Shape**                 | Needle/rod/rhomboid, single/annular/fan-like | Rhomboid shape, in clusters/rosette-like | Elongated/rectangular large collections |
| **Distribution**          | Tubular lumen/cytoplasm | Tubular lumen/cytoplasm | Interstitium (medullary) |
|                           | Interstitium (cortical) | Interstitium (cortical) | Interstitium (medullary) |
| **Giant-cell reaction**   | Sometimes          | Sometimes                    | Common                       |
| **Birefringence**         | Yes                | Yes                          | Dissolve in formalin-fixed tissue |

H&E, haematoxylin and eosin; PAS, periodic acid–Schiff; 2,8 DHA, 2,8 dihydroxyadenine.
Since DHA stones are radiolucent, they are usually first diagnosed on ultrasonography or computed tomography scan either incidentally or during work up for nephropathy. A careful urinary examination is usually sufficient to diagnose DHA stones. However, the diagnosis can be confirmed by biochemical stone analysis, APRT enzyme assays from erythrocyte lysate, and genetic analysis by sequencing, which has shown more than 40 mutations of the APRT gene.

Renal biopsy plays a very important role in patients with renal dysfunction in the absence of renal stones. The renal histopathology in patients with APRT deficiency is characterized by diffuse DHA crystal deposition and tubulointerstitial abnormalities. As with urine microscopy, the DHA crystal appearance may be differentiated from hyperoxaluria and hyperuricemia (Table 1). It has been studied that evaluation of crystals in urine samples/renal biopsy by Fourier transform infrared microscopy are highly specific, and measurement of APRT activity level in erythrocyte lysate should also be done for final confirmation of the diagnosis. Genetic testing may be done, but it is not necessary for diagnosis. These diagnostic modalities are not freely available (especially in underdeveloped countries), and a careful urine examination and kidney biopsy evaluation are often sufficient for reaching the diagnosis.

We reviewed other cases of DHA crystal nephropathy in the English published literature (Table 2). To the best of our knowledge, ours is the third case reported from India [7,8]. However, the patient in our case did not have a history of renal stones preceding development of renal failure.

Timely recognition of the crystals in urine or on biopsy is important because initiating a purine-poor diet can retard the formation of crystals, and strong diuresis can wash out already-formed crystals. Recently, the nonpurine XDH inhibitor febuxostat has been used as an alternative therapeutic option. Edvardsson et al [9] compared the effects of both drugs on level of urinary 2,8 DHA excretion in a small cohort of patients and found significant reduction in DHA excretion with febuxostat.

In conclusion, DHA crystals can be easily diagnosed by their pathognomic color and shape in urine and biopsy specimens. Due consideration should be given to a young patient presenting with acute or CKD with nephropathy and crystals in the urine without urolithiasis. A high index of clinical suspicion helps in the early diagnosis of this potentially treatable renal disease.

### Table 2. Comparison of the clinicopathological features and treatments in Indian studies

| Parameter                  | Sreejith et al [7] | Krishnappa et al [8] | Present case |
|----------------------------|--------------------|----------------------|--------------|
| Age (yr)/sex               | 3/female           | 2/female             | 24/female    |
| Clinical presentation      | Anuria             | Hematuria, UTI       | RPRF         |
| History of graveluria      | No                 | Not mentioned        |              |
| Serum creatinine (mg/dL)   | 3.6                | 0.4                  | 2.4          |
| Ultrasonography            | Radiolucent stones in right calyx and ureter | Radiolucent stones in right calyx, PUJ hydronephrosis | No stones |
| Urinalysis                 | ND                 | Active sediments with crystals | Crystals with no active sediments |
| Renal biopsy               | ND                 | ND                   | Crystals with TIN |
| Treatment                  | Peritoneal dialysis | Nephrolithotomy     | Allopurinol |
| Additional tests           | Infrared spectroscopy | Infrared spectroscopy | Genetic analysis (not done) |

ND, not done; PUJ, pelviuretric junction; RPRF, rapidly progressive renal failure; TIN, tubulointerstitial nephritis; UTI, urinary tract infection.

### Conflicts of interest

All authors have no conflicts of interest to declare.

### References

[1] Finn LS. Renal disease caused by inborn error of metabolism, storage diseases, and hemoglobinopathies. In: Jeneatte JC, Olson JL, Silva FG, D’Agati VD, eds. Heptinstall’s Pathology of the Kidney, 7th edition. Philadelphia: Lippincott Williams & Wilkins, 1252-1253, 2015

[2] Mac-Way F, Desmeules S, Latulippe E, de Cotret PR, Agharazii M. 2,8-Dihydroxyadeninuria-induced progres-
sive renal failure. NDT Plus 1:437-439, 2008

[3] Brown HA. Recurrence of 2,8-dihydroxyadenine tubulo-interstitial lesions in a kidney transplant recipient with a primary presentation of chronic renal failure. Nephrol Dial Transplant 13:998-1000, 1998

[4] Zaidan M, Palsson R, Merieau E, et al. Recurrent 2,8-dihydroxyadenine nephropathy: a rare but preventable cause of renal allograft failure. Am J Transplant 14:2623-2632, 2014

[5] Bollee G, Daudon M, Ceballos-Picot I. Adenine phosphoribosyltransferase deficiency: Leave no stone unturned. World J Clin Urol 3:218-226, 2014

[6] Bollée G, Dollinger C, Boutaud L, et al. Phenotype and genotype characterization of adenine phosphoribosyltransferase deficiency. J Am Soc Nephrol 21:679-688, 2010

[7] Sreejith P, Narasimhan KL, Sakhuja V. 2, 8 Dihydroxyadenine urolithiasis: A case report and review of literature. Indian J Nephrol 19:34-36, 2009

[8] Krishnappa P, Krishnamoorthy V, Gowda KK. Dihydroxyadenine stone with adenine phosphoribosyltransferase deficiency: A case report. Indian J Urol 33:246-248, 2017

[9] Edvardsson VO, Runolfsdottir HL, Thorsteinsdottir UA, et al. Comparison of the effect of allopurinol and febuxostat on urinary 2,8-dihydroxyadenine excretion in patients with adenine phosphoribosyltransferase deficiency (APRTd): A clinical trial. Eur J Intern Med 48:75-77, 2018